Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1367-1373

  Goodman, Vicki L ^a   Rock, Edwin P ^a   Dagher, Ramzi ^a   Ramchandani, Roshni P ^a   Abraham, Sophia ^a   Gobburu, Jogarao V S ^a   Booth, Brian P ^a   Verbois, S Leigh ^a   Morse, David E ^a   Liang, Cheng Yi ^a   Chidambaram, Nallaperumal ^a   Jiang, Janet X ^a   Tang, Shenghui ^a   Mahjoob, Kooros ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; IMATINIB; KETOCONAZOLE; PLACEBO; SUNITINIB;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIMB PAIN; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN DISEASE; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PIPERAZINES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33947423448     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2328     Document Type: Article

References (19)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
2. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RMC, Hogendoom PCW. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer 2005;41:2868-72.
3. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002;38:S37-8.
4. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
5. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.
6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80.
7. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-34.
8. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
9. Cohen HT, McGovern, FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
10. Medical Research Council Renal Cancer Collaborative. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
11. Minasian LM, Motzer RJ, Gluck L, Mazumder M, VlamisV, Krown SE. Interferon α-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368-75.
12. Atkins MB, Regan M, McDermott D. Update on the role of interleukin-2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342-6S.
13. Physicians' Desk Reference. 59th ed. Montvale (NJ): Thomson PDR; 2005.
14. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
15. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
16. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 1999;17:2039-43.
17. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22: 454-63.
18. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-8.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-16.